Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and biotech investing. Bret reflects on lessons he learned at Alnylam about the power of genetically validated drug targets and the importance of team culture, why CNS drug development fails so often, and the problem with animal models. He also tal...